CytomX Therapeutics (CTMX) EBITDA Margin (2014 - 2026)
CytomX Therapeutics (CTMX) reported EBITDA Margin of 177.98% for Q1 2026, down 22413.0% on a YoY basis from N/an in Q1 2025, and up 87.13% quarter-over-quarter from 1382.5% in Q4 2025.
CytomX Therapeutics (CTMX) EBITDA Margin (2014 - 2026) Analysis & Trends
CytomX Therapeutics has reported EBITDA Margin for 13 years, with the latest figure at 177.98% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 22413.0% year-over-year to 177.98%; the trailing twelve-month figure through Mar 2026 stood at 117.33% (down 14553.0% YoY), and the FY2025 full-year result was 4.72%, down 2775.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 177.98%, up from 1382.5% in the prior quarter.
- The five-year high for EBITDA Margin was 49.52% in Q4 2024, with the low at 1382.5% in Q4 2025.
- Historically, EBITDA Margin has averaged 151.29% across 5 years, with a median of 14.02% in 2023.
- Annual changes were most pronounced in 2023 — EBITDA Margin soared 34724 bps — and 2025, when it plunged 143202 bps.
- CytomX Therapeutics' EBITDA Margin stood at 39.61% in 2022, then soared by 109 bps to 3.74% in 2023, then surged by 1224 bps to 49.52% in 2024, then sank by 2892 bps to 1382.5% in 2025, then surged by 87 bps to 177.98% in 2026.
- The last three EBITDA Margin figures came in at 177.98% (Q1 2026), 1382.5% (Q4 2025), and 237.43% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | CytomX Therapeutics | 520.30 Mn | 173.59 Mn | - | -177.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -177.98% |
| Dec 31, 2025 | -1,382.50% |
| Sep 30, 2025 | -237.43% |
| Jun 30, 2025 | -0.64% |
| Mar 31, 2025 | 46.15% |
| Dec 31, 2024 | 49.52% |
| Sep 30, 2024 | 17.29% |
| Jun 30, 2024 | -25.99% |
| Mar 31, 2024 | 33.01% |
| Dec 31, 2023 | 3.74% |
| Sep 30, 2023 | 10.97% |
| Jun 30, 2023 | -4.36% |
| Mar 31, 2023 | -14.02% |
| Dec 31, 2022 | -39.61% |
| Sep 30, 2022 | -257.44% |
| Jun 30, 2022 | -231.38% |
| Mar 31, 2022 | -361.26% |
| Dec 31, 2021 | -315.46% |
| Sep 30, 2021 | -336.76% |
| Jun 30, 2021 | -303.33% |